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Human Toxicity of PBDDs and
PBDFs
The brillant literature review and health
risk assessment by Mennear and Cheng-
Chung, "Polybrominated Dibenzo-p-diox-
ins and Dibenzofurans: Literature Review
and Health Assessment" [EHP 102(suppl
1):265-274], states that "reports ofhuman
toxicity associated with exposure to
PBDDs and PBDFs were not found" (p.
272). In fact, in their review, no references
are discussed or quoted regarding human
studies.
Two papers have been published on the
human toxicology ofthese compounds. The
first (1) is a recent report, previously pre-
sented at the Dioxin '90 Congress (2), about
a chemist who was exposed to 2,3,7,8,-
tetrabromodibenzodioxin (TBDD) and to
2,3,7,8-tetrachlorodibenzodioxin (TCDD)
in March and September 1956, respective-
ly, when synthesizing these chemicals. The
chemist was defined as "in good health" in
1990, when determinations of chlorinated
and brominated dioxins and dibenzofurans
were performed on whole blood. High
concentrations of several congeners were
detected, and the results were used to dis-
cuss the half-life of the chemicals in
humans. The subject presented a mild
chloracne after an unspecified time from
his exposure to bromodixoins in March,
suggesting that TBDD could produce skin
effects as chlorodioxins. Other more rele-
vant symptoms occurred after the exposure
to TCDD in September, and the patient
was hospitalized for a short period.
The second was a study of subjects
exposed to PBDDs and PBDFs as a result
of working at a BASF factory in etrusion
blending of polybutyleneterphthalate with
decarbromodiphenyl ether, used as a flame
retardant. The intensity of exposure was
determined in 1989 through air monitor-
ing (3). The paper presents blood levels of
2,3,7,8,-TBDF and TBDD and of total
congener profiles for some exposed work-
ers and the results of a comparison of sev-
eral immunological tests in a population of
exposed versus a population of unexposed
deriving from the same working cohort.
Workers had detectable blood levels of
TBDD and TBDF; half-life estimates of
these chemicals are presented. The results
of immunological tests were described as
"not adversely impacted at these burdens
of PBDFs and PBDDs," even though the
results ofseveral tests showed a correlation
with exposure, and in the subject having
the highest blood levels of PBDFs and
PBDDs, immunological changes were
quite relevant. The authors stated that clin-
ical examination did not reveal "skin
lesions consistent with an acnegenic
response.
It should be stressed that the results of
the two quoted articles do not change the
conclusions of Mennear and Cheng-
Chung on the health risks of PBDDs and
PBDFs. However, slightly different sugges-
tions for future research can be derived.
Human populations have been or are
exposed to these chemicals because oftheir
use in several work processes involving
flame retardants, environmental exposures
(mainly due to municipal incinerators), or
because of accidents due to thermal de-
composition of flame retardants. These
exposed human populations can be suit-
able, at least in theory, for toxicological
and epidemiological observations.
Enzo Merler
Eva Buiatti
Centre for the Study and Prevention of
Cancer
Florence, Italy
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Arsenic Risk Assessment
A commentary highly critical oftwo ofour
published studies was recently published in
EnvironmentalHealth Perspectives (Carlson-
Lynch et al., 102:354-356). One of our
papers examines the epidemiological evi-
dence for a methylation threshold for inor-
ganic arsenic and concludes that there is no
consistent evidence to support the hypoth-
esis ofsuch a threshold in humans (1). The
second paper critiqued by Carlson-Lynch
et al. estimates the human cancer risks of
arsenic at internal sites (lung, liver, kidney,
and bladder) using linear extrapolation
from Taiwanese data (2). Carlson-Lynch et
al. contend that the analyses conducted in
our studies are flawed and that the conclu-
sions reached in our publications are erro-
neous, rendering them unsuitable for use
by the EPA in risk assessment.
Whether or not our studies are used by
the EPA for risk assessment is oflittle con-
cern to us, but we are certainly concerned
about statements that they are flawed.
Careful examination will show that all of
the major points raised in the commentary
are either incorrect or have no valid basis.
We would like to respond to the criticisms
made, point by point, in the order present-
ed, beginning with the methylation paper
(1).
Critique: The average arsenic exposures
in almost all of the studies analyzed were
too low to observe methylation saturation.
Response: The commentators base this
statement on three issues. First, the authors
state that evidence from an experimental
study (ofonly four human volunteers each
receiving only one dose level) suggests that
methylation would be completely saturated
at exposures greater than 500 pg/day (3).
However, at the highest oral dose in this
study, 1000 pg/day, the amount ofurinary
arsenic in the inorganic form was only
26%, hardly demonstrating methylation
saturation even at this level. Buchet et al.
(3) state in their paper that "speciation of
the arsenic metabolites in urine indicated
that the arsenic methylation capacity ofthe
human body was not yet saturated, even
with an oral daily dose of 1000 pg As."
The evidence of any metabolic saturation
from this study is not conclusive. Each of
four arsenic dosing levels was assigned to a
different individual subject, making it
impossible to differentiate interindividual
differences in methylation efficiency from
dose-dependent effects that might apply to
a general population.
Second, the authors state that we ana-
lyzed only two groups with average urinary
arsenic levels at or above 190 pg/I, which
theyhypothesize corresponds to the concen-
tration above which methylation saturation
occurs. This statement obscures the fact that
1) the two groups combined had a total of
35 people, 2) our analysis ofavailable indi-
vidual data (see Figure 2 of our paper)
included 14 persons with urinary arsenic
levels >190 pg/l. No trend ofhigher relative
proportions ofunmethylated arsenic is sug-
gested for those 14 individuals.
Third, the authors state: ". . . a regres-
sion analysis on the individual data within
the Yamauchi et al. [4] population was bor-
derline significant atp = 0.10. . ." (p. 354).
However, this was just one of nine regres-
sion analyses we presented. The slopes were
positive in four (including the Yamauchi
study) but negative in five (1: Table 9).
As a matter of interest, in our more
recent studies ofchronically exposed popu-
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